Charcot-Marie-Tooth Disease with Myelin Protein Zero Mutation Presenting as Painful, Predominant Small-Fiber Neuropathy

Int J Mol Sci. 2024 Jan 29;25(3):1654. doi: 10.3390/ijms25031654.

Abstract

Charcot-Marie-Tooth disease (CMT) rarely presents with painful symptoms, which mainly occur in association with myelin protein zero (MPZ) gene mutations. We aimed to further characterize the features of painful neuropathic phenotypes in MPZ-related CMT. We report on a 58-year-old woman with a longstanding history of intermittent migrant pain and dysesthesias. Examination showed minimal clinical signs of neuropathy along with mild changes upon electroneurographic examination, consistent with an intermediate pattern, and small-fiber loss upon skin biopsy. Genetic testing identified the heterozygous variant p.Trp101Ter in MPZ. We identified another 20 CMT patients in the literature who presented with neuropathic pain as a main feature in association with MPZ mutations, mostly in the extracellular MPZ domain; the majority of these patients showed late onset (14/20), with motor-nerve-conduction velocities predominantly in the intermediate range (12/20). It is hypothesized that some MPZ mutations could manifest with, or predispose to, neuropathic pain. However, the mechanisms linking MPZ mutations and pain-generating nerve changes are unclear, as are the possible role of modifier factors. This peculiar CMT presentation may be diagnostically misleading, as it is suggestive of an acquired pain syndrome rather than of an inherited neuropathy.

Keywords: Charcot–Marie–Tooth disease; myelin protein zero; neuropathic pain; skin biopsy.

Publication types

  • Case Reports

MeSH terms

  • Charcot-Marie-Tooth Disease* / diagnosis
  • Charcot-Marie-Tooth Disease* / genetics
  • Female
  • Genetic Testing
  • Humans
  • Middle Aged
  • Mutation
  • Myelin P0 Protein / genetics
  • Neuralgia* / etiology
  • Neuralgia* / genetics
  • Small Fiber Neuropathy* / genetics

Substances

  • Myelin P0 Protein

Grants and funding

This study was partially supported by the Fondazione Emma ed Ernesto Rulfo per la Genetica Medica.